Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

Community and Patient Preference Research Pty Ltd

Overview

A real world evidence study that aims to understand the impact of RYALTRIS® nasal spray in patients with Allergic Rhinitis over a 28-day period.

The aim of this research is to develop a greater understanding of satisfaction with RYALTRIS® nasal spray in patients with Allergic Rhinitis (AR). There is currently no real-world evidence for patient satisfaction data with RYALTRIS® nasal spray. To address this knowledge gap and add to clinically relevant data to support Quality of Life (QoL) and patient reported outcomes, this research will evaluate the impact on quality of life (symptom control), using a Visual Analogue Scale (VAS), following initiation of RYALTRIS® to explore the relationship between baseline and subsequent QoL scores among patients initiated on RYALTRIS®.

Study Type

OBSERVATIONAL

Conditions

Allergic Rhinitis

Interventions

ObservationalOTHER

In this observational study, participants with moderate to severe Allergic Rhinitis who were initiated on Ryaltris® nasal spray by their healthcare professional will complete an online survey before commencement of treatment and then at days 1, 7, and 14 from treatment initiation. Survey completion at day 28 after treatment initiation will be optional for participants based on ongoing use of RYALTRIS®.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: AR patients (moderate-to-severe SAR or PAR) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study: * Patients above 18 years old * Fluent in English * Patients newly prescribed RYALTRIS® who have not yet initiated treatment * Willing and able to provide consent to participate Exclusion Criteria: Potential participants will be excluded if they: * Are employed by a pharmaceutical company (to avoid conflict of interest) * Are employed by a vaccine company (to avoid conflict of interest) * Do not have access to the internet (to ensure validity of the data) * Are unable to read and understand English (to ensure validity of the data) * are currently or have previously been on RYALTRIS®

Locations (1)

Community and Patient Preference Research Pty Ltd

Sydney, New South Wales, Australia

Outcomes

Primary Outcomes

Visual analogue scale (VAS)

The primary study endpoint is the overall VAS score to determine improvement of Allergic Rhinitis symptoms and quality of life.

Time frame: 28 days

Secondary Outcomes

Overall Allergic Rhinitis nasal symptoms

Response to a visual analogue scale about their Allergic Rhinitis nasal symptoms

Time frame: 28 days

Overall Allergic Rhinitis ocular symptoms

Response to a visual analogue scale about their Allergic Rhinitis ocular symptoms

Time frame: 28 days

Sleep quality

Response to a visual analogue scale about their sleep quality

Time frame: 28 days

Daily outdoor activities

Response to a visual analogue scale about their daily outdoor activities

Time frame: 28 days

Work productivity

Response to a visual analogue scale about their work productivity

Time frame: 28 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.